The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

UCLA researchers have developed a lipid nanoparticle-based gene-editing approach capable of inserting an entire healthy gene into human airway cells, restoring key biological function in a laboratory ...

Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now ...

Ed Carlson, CVT, VTS (Nutrition), shares how routine body and muscle scoring, quantified nutrition histories, clear calorie ...

In the centenarian ‘Blue Zone’ of Okinawa, its sprightly residents swear by joy, movement and good food as secret to long life ...

In the modern world, the human body is besieged by a silent category of chemicals that interfere with one of its most ...

Vinicius Oliveira is not a small Bantamweight. “Lokdog” stands at 5’9”, which in itself is tall but not outrageous for a 135-pounder. However, he’s no string bean, and all of his opponents who clinch ...

Celestica faces heightened downside risk if AI sector sentiment sours further. Read more about CLS stock and why I'm staying ...

Guterres warns against erosion of international law and cooperation Multilateralism under assault, secretary-general says, amid global conflicts, US funding cuts Guterres prioritizes AI governance to ...

Roche Holdings AG (OTC: RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual ...

Please provide your email address to receive an email when new articles are posted on . Adults receiving 24 mg of CT-388 achieved a placebo-adjusted weight loss of 22.5% according to the efficacy ...

Consumer sentiment for Windows 11 has been on a downward trajectory of late, at least if the reactions to Microsoft executives are any indicator. Although it's hard to quantify broad user sentiment, ...